118 related articles for article (PubMed ID: 12224511)
1. Avoiding proteasomal processing: the case of EBNA1.
Dantuma NP; Sharipo A; Masucci MG
Curr Top Microbiol Immunol; 2002; 269():23-36. PubMed ID: 12224511
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
Levitskaya J; Sharipo A; Leonchiks A; Ciechanover A; Masucci MG
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12616-21. PubMed ID: 9356498
[TBL] [Abstract][Full Text] [Related]
3. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.
Yin Y; Manoury B; Fåhraeus R
Science; 2003 Sep; 301(5638):1371-4. PubMed ID: 12958359
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal.
Dantuma NP; Heessen S; Lindsten K; Jellne M; Masucci MG
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8381-5. PubMed ID: 10890896
[TBL] [Abstract][Full Text] [Related]
5. Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition.
Tellam J; Sherritt M; Thomson S; Tellam R; Moss DJ; Burrows SR; Wiertz E; Khanna R
J Biol Chem; 2001 Sep; 276(36):33353-60. PubMed ID: 11435434
[TBL] [Abstract][Full Text] [Related]
6. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
Lee SP; Brooks JM; Al-Jarrah H; Thomas WA; Haigh TA; Taylor GS; Humme S; Schepers A; Hammerschmidt W; Yates JL; Rickinson AB; Blake NW
J Exp Med; 2004 May; 199(10):1409-20. PubMed ID: 15148339
[TBL] [Abstract][Full Text] [Related]
7. Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing.
Zhang M; Coffino P
J Biol Chem; 2004 Mar; 279(10):8635-41. PubMed ID: 14688254
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1.
Blake NW; Moghaddam A; Rao P; Kaur A; Glickman R; Cho YG; Marchini A; Haigh T; Johnson RP; Rickinson AB; Wang F
J Virol; 1999 Sep; 73(9):7381-9. PubMed ID: 10438828
[TBL] [Abstract][Full Text] [Related]
9. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Moss DJ; Kurilla MG; Cooper L
Int Immunol; 1997 Oct; 9(10):1537-43. PubMed ID: 9352359
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
11. cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition.
Sharipo A; Imreh M; Leonchiks A; Brändén C; Masucci MG
FEBS Lett; 2001 Jun; 499(1-2):137-42. PubMed ID: 11418128
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies.
Dantuma NP; Masucci MG
Semin Cancer Biol; 2003 Feb; 13(1):69-76. PubMed ID: 12507558
[TBL] [Abstract][Full Text] [Related]
13. TAP-independent antigen presentation on MHC class I molecules: lessons from Epstein-Barr virus.
Lautscham G; Rickinson A; Blake N
Microbes Infect; 2003 Apr; 5(4):291-9. PubMed ID: 12706442
[TBL] [Abstract][Full Text] [Related]
14. Epstein Barr virus-encoded EBNA1 interference with MHC class I antigen presentation reveals a close correlation between mRNA translation initiation and antigen presentation.
Apcher S; Daskalogianni C; Manoury B; Fåhraeus R
PLoS Pathog; 2010 Oct; 6(10):e1001151. PubMed ID: 20976201
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ubiquitin-dependent proteolysis by a synthetic glycine-alanine repeat peptide that mimics an inhibitory viral sequence.
Leonchiks A; Stavropoulou V; Sharipo A; Masucci MG
FEBS Lett; 2002 Jul; 522(1-3):93-8. PubMed ID: 12095625
[TBL] [Abstract][Full Text] [Related]
16. Immunology. Hide and seek in the peptidome.
Yewdell JW
Science; 2003 Sep; 301(5638):1334-5. PubMed ID: 12958347
[No Abstract] [Full Text] [Related]
17. A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis.
Sharipo A; Imreh M; Leonchiks A; Imreh S; Masucci MG
Nat Med; 1998 Aug; 4(8):939-44. PubMed ID: 9701247
[TBL] [Abstract][Full Text] [Related]
18. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.
Tellam J; Connolly G; Green KJ; Miles JJ; Moss DJ; Burrows SR; Khanna R
J Exp Med; 2004 May; 199(10):1421-31. PubMed ID: 15148340
[TBL] [Abstract][Full Text] [Related]
19. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
Ressing ME; Horst D; Griffin BD; Tellam J; Zuo J; Khanna R; Rowe M; Wiertz EJ
Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
